drugset / Trial / NCT02554019

Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus

NCT02554019 ↗

Phase 2 Completed 36 enrolled Biotest
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of repeated intravenous infusions of the study drug BT063 in patients with Systemic Lupus Erythematosus (SLE) compared with people who receive a placebo.

Timeline

Start
2015-09-28
Primary completion
2017-10-25
Completion
2017-10-25

Drugs

EvaluationDrugModalityDoseRoute
Subject BT063 Unknown 50 mg Intravenous